RXRX vs. VIR

The year-to-date returns for both investments are quite close, with RXRX having a -14.94% return and VIR slightly higher at -14.31%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Vir Biotechnology, Inc. (VIR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RXRX Sharpe Ratio is -0.27, which is comparable to the VIR Sharpe Ratio of -0.25. The chart below compares the historical Sharpe Ratios of RXRX and VIR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RXRX nor VIR has paid dividends to shareholders.

The maximum RXRX drawdown since its inception was -90.39%, roughly equal to the maximum VIR drawdown of -93.75%. Use the drawdown chart below to compare losses from any high point for RXRX and VIR. For additional features, visit the drawdowns tool.

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 38.31% compared to Vir Biotechnology, Inc. (VIR) at 22.41%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than VIR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Vir Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.